Development Strategy

Pega-One is working on a long-term clinical development program, leveraging the unique properties of imgatuzumab to develop innovative, promising combination therapies addressing hard to treat patient populations with EGFR expressing solid tumors.

Initial focus is on three promising combination pathways:

1. With an PD(L)-1 inhibitor and immunotherapy across multiple EGFR        expressing tumors

2. With an anti KRASG12C to address difficult to treat solid tumors

3. With ex-vivo engineered        NK-Cell cells to enhance innate immune response

Pega-One is participating in the REMISSION Research project of the Institute Gustave Roussy, Paris,  studying imgatuzumab with or without a checkpoint inhibitor in neo-adjuvant Squamous Cell Cancer of the Head & Neck.